Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -76K | -96K | -65K | -3M | -15K |
| EBITDA | -76K | -96K | -65K | -3M | -15K |
| Net Income | -76K | -96K | -65K | -3M | -15K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.444
+119.80% today
1Y Change
-35.65%
Window
Jun 26, 2025 → Jun 24, 2026
Coverage: 251 bars · Jun 26, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nika Pharmaceuticals Inc. (NIKA) is a Healthcare stock with a market cap of $420.00M and listed on OTC. The stock last traded around $0.44 and down 35.7% across the available one-year price window (Jun 26, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow +42.7% with operating margin 0.0% and ROIC 25.7%. Stock Foundry combines NIKA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NIKA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NIKA Max Drawdown
-79.11%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for NIKA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$14.7K
+99.5% YoY
Free Cash Flow
-$14.7K
+56.4% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -76K | -96K | -65K | -3M | -15K |
| EBITDA | -76K | -96K | -65K | -3M | -15K |
| Net Income | -76K | -96K | -65K | -3M | -15K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2K | 2K | 20K | 864 | 399 |
| Total Assets | 21K | 18K | 20K | 864 | 399 |
| Total Liabilities | 319K | 239K | 102K | 18K | 24K |
| Shareholder Equity | -298K | -221K | -82K | -17K | -24K |
| Total Debt | 0 | 239K | 102K | 18K | 24K |
| Net Debt | -2K | 237K | 82K | 17K | 24K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
15K
+56.4% YoY
Capital Expenditures
0
Free Cash Flow
15K
+56.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
29.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.